18F-fluorocholine and 18F-fluoride PET in Prostate Cancer
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Prostate cancer remains to be a public health problem around the world. For patients with
prostate cancer, diphosphonate bone scintigraphy (BS) and pelvic tomographic imaging are
major imaging tools to evaluate the disease spread. However, the conventional image
modalities have only limited sensitivity and specificity. New imaging tracer with
18F-fluorocholine (18F-FCH) and old radiopharmaceuticals with NaF has showed promising
results in detecting prostate cancers over bone scan. Nevertheless, the diagnostic
performance of each tool has less been compared.
The goal of this study is to compare the diagnostic performance of 18F-FCH PET/CT and NaF
PET/CT for prostate cancer patients.
The investigators prospectively enroll patients with the pathological diagnosis of prostate
cancer and intended to receive radionuclide bone image. The patients will receive NaF PET/CT
and 18F-FCH PET/CT. Each image will be evaluated by experienced interpreter for abnormal
uptake suspicious for cancer spreading. The reference standard will be a combination of
tissue correlation, imaging, laboratory and clinical data. Diagnostic performance of both
PET/CT scans will be measured and calculated.